Payment overview · 2025
General Payments
$498.34
29 reported records · 12 companies
Healthcare provider profile · identity verified
Guillermo Madero, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN ANTONIO, TX · NPI 1235384439
Verified facts
What the public records show
CMS Open Payments records show Guillermo Madero, MD received $498.34 in general payments during 2025 across 29 reported records.
Novo Nordisk Inc accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 167 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $137.02 | 27.5% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $94.65 | 19.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.98 | 14.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $40.40 | 8.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.25 | 7.3% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $20.80 | 4.2% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.16 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.21 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.95 | 3.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.87 | 3.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.71 | 3.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.34 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $498.34 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $94.65 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.98 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $71.64 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.32 | 5 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $20.80 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.95 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $12.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 167 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
163 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
167 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 939 | 310 |
| Lisinopril | Lisinopril | 573 | 191 |
| Losartan Potassium | Losartan Potassium | 478 | 154 |
| Metformin Hcl | Metformin Hcl | 414 | 144 |
| Amlodipine Besylate | Amlodipine Besylate | 412 | 137 |
| Gabapentin | Gabapentin | 372 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 101 |
| Tizanidine Hcl | Tizanidine Hcl | 273 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 229 | 81 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 219 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 73 |
| Omeprazole | Omeprazole | 176 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 58 |
| Ozempic | Semaglutide | 167 | 36 |
| Jardiance | Empagliflozin | 163 | 57 |
| Montelukast Sodium | Montelukast Sodium | 160 | 61 |
| Pravastatin Sodium | Pravastatin Sodium | 158 | 51 |
| Carvedilol | Carvedilol | 152 | 56 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 151 | 56 |
| Famotidine | Famotidine | 149 | 51 |
| Trazodone Hcl | Trazodone Hcl | 145 | 54 |
| Tramadol Hcl | Tramadol Hcl | 141 | 39 |
| Alendronate Sodium | Alendronate Sodium | 131 | 43 |
| Glipizide | Glipizide | 131 | 46 |
| Furosemide | Furosemide | 127 | 45 |
| Sertraline Hcl | Sertraline Hcl | 124 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 39 |
| Metformin Hcl Er | Metformin Hcl | 101 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 94 | 21 |
| Eliquis | Apixaban | 84 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 79 | 33 |
| Ketoconazole | Ketoconazole | 77 | 51 |
| Nifedipine Er | Nifedipine | 75 | 33 |
| Celecoxib | Celecoxib | 72 | 23 |
| Enalapril Maleate | Enalapril Maleate | 72 | 22 |
| Ibuprofen | Ibuprofen | 71 | 31 |
| Finasteride | Finasteride | 69 | 24 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 69 | 31 |
| Simvastatin | Simvastatin | 68 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 67 | 21 |
| Januvia | Sitagliptin Phosphate | 67 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 67 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | 35 |
| Trulicity | Dulaglutide | 66 | 15 |
| Cephalexin | Cephalexin | 65 | 58 |
| Mounjaro | Tirzepatide | 65 | 12 |
| Pregabalin | Pregabalin | 64 | 18 |
| Buspirone Hcl | Buspirone Hcl | 63 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 25 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 61 | 25 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 60 | 50 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 57 | 16 |
| Prednisone | Prednisone | 57 | 50 |
| Ezetimibe | Ezetimibe | 56 | 25 |
| Meclizine Hcl | Meclizine Hcl | 56 | 27 |
| Allopurinol | Allopurinol | 54 | 22 |
| Myrbetriq | Mirabegron | 52 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 50 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | 25 |
| Donepezil Hcl | Donepezil Hcl | 46 | 17 |
| Glimepiride | Glimepiride | 46 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Farxiga | Dapagliflozin Propanediol | 42 | 13 |
| Potassium Chloride | Potassium Chloride | 42 | 20 |
| Topiramate | Topiramate | 41 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 39 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | 12 |
| Valsartan | Valsartan | 39 | 13 |
| Levetiracetam | Levetiracetam | 37 | suppressed |
| Rybelsus | Semaglutide | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 14 |
| Linzess | Linaclotide | 35 | 13 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 33 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Meloxicam | Meloxicam | 31 | 12 |
| Alprazolam | Alprazolam | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Glipizide Er | Glipizide | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Ciclopirox | Ciclopirox | 27 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | 11 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Azithromycin | Azithromycin | 20 | 19 |
| Lactulose | Lactulose | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | 11 |
| Spironolactone | Spironolactone | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | 11 |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Tradjenta | Linagliptin | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $498.34 · 29 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Barostim Neo System, CAPVAXIVE, COMIRNATY, CRYSVITA, FREESTYLE LIBRE 3, Kerendia, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, Wegovy, XIFAXAN | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error